

(51) International Patent Classification:
A61K 31/7068 (2006.01)(21) International Application Number:
PCT/US2022/024286(22) International Filing Date:
11 April 2022 (11.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/173,354	09 April 2021 (09.04.2021)	US
63/175,673	16 April 2021 (16.04.2021)	US
63/210,246	14 June 2021 (14.06.2021)	US
63/288,163	10 December 2021 (10.12.2021)	US
63/298,836	12 January 2022 (12.01.2022)	US

(71) Applicant: **EMORY UNIVERSITY** [US/US]; 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322 (US).

(72) Inventors: **SCHINAZI, Raymond**; 1000 Biscayne Boulevard, Apt. 4001, Miami, Florida 33132 (US). **AMBLARD, Franck**; c/o Emory University, 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322 (US). **KASTHURI, Mahesh**; c/o Emory University, 1599 Clifton Road NE, 4th

Floor, Atlanta, Georgia 30322 (US). **BITEAU, Nicolas**; c/o Emory University, 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322 (US). **SHI, Junxing**; c/o Emory University, 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322 (US). **ZHOU, Longhu**; c/o Emory University, 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322 (US). **ZANDI, Keivan**; c/o Emory University, 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322 (US).

(74) Agent: **BRADIN, David**; 4141 Parklake Avenue, Suite 200, Raleigh, North Carolina 27612 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS




FIG. 1B

(57) Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1, OC43, and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavirus, Togavirus, or Bunyavirus.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*